CG Oncology, Inc. Operating Lease, Payments
CG Oncology, Inc. (CGON) reported Operating Lease, Payments of $345.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- CG Oncology, Inc. operating lease, payments for the quarter ending 2026-06-30 was $345.00K, a 301.16% increase year-over-year.
- CG Oncology, Inc. operating lease, payments for the quarter ending 2026-03-31 was $310.00K, a 313.33% increase year-over-year.
- CG Oncology, Inc. operating lease, payments for the quarter ending 2025-12-31 was $205.00K, a 241.67% increase year-over-year.
- CG Oncology, Inc. operating lease, payments for the quarter ending 2025-09-30 was $222.00K, a 270.00% increase year-over-year.
- CG Oncology, Inc. operating lease, payments for fiscal 2025 was $588.00K, a 163.68% increase from fiscal 2024.
- CG Oncology, Inc. operating lease, payments for fiscal 2024 was $223.00K, a 1.83% increase from fiscal 2023.
- CG Oncology, Inc. operating lease, payments for fiscal 2023 was $219.00K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $345.00K 10-Q · filed 2026-08-06 | $654.00K 10-Q · filed 2026-08-06 | $860.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $310.00K 10-Q · filed 2026-05-08 | $515.00K derived: sum of 2 quarters · filed 2026-05-08 | $737.00K derived: sum of 3 quarters · filed 2026-05-08 | $823.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $427.00K derived: sum of 2 quarters · filed 2026-02-27 | $513.00K derived: sum of 3 quarters · filed 2026-08-06 | $588.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $222.00K 10-Q · filed 2025-11-14 | $308.00K derived: sum of 2 quarters · filed 2026-08-06 | $383.00K 10-Q · filed 2025-11-14 | $443.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $86.00K 10-Q · filed 2026-08-06 | $161.00K 10-Q · filed 2026-08-06 | $221.00K derived: sum of 3 quarters · filed 2026-08-06 | $281.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $75.00K 10-Q · filed 2026-05-08 | $135.00K derived: sum of 2 quarters · filed 2026-05-08 | $195.00K derived: sum of 3 quarters · filed 2026-05-08 | $240.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $120.00K derived: sum of 2 quarters · filed 2026-02-27 | $165.00K derived: sum of 3 quarters · filed 2026-02-27 | $223.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $60.00K 10-Q · filed 2025-11-14 | $105.00K derived: sum of 2 quarters · filed 2025-11-14 | $163.00K 10-Q · filed 2025-11-14 | $221.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $45.00K 10-Q · filed 2025-08-08 | $103.00K 10-Q · filed 2025-08-08 | $161.00K derived: sum of 3 quarters · filed 2025-08-08 | $220.00K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $58.00K 10-Q · filed 2025-05-13 | $116.00K derived: sum of 2 quarters · filed 2025-05-13 | $175.00K derived: sum of 3 quarters · filed 2025-05-13 | $220.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $117.00K derived: sum of 2 quarters · filed 2025-03-28 | $162.00K derived: sum of 3 quarters · filed 2025-03-28 | $219.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $59.00K 10-Q · filed 2024-11-12 | $104.00K derived: sum of 2 quarters · filed 2024-11-12 | $161.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $45.00K 10-Q · filed 2024-08-08 | $102.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $58.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |